Intraductal Tubular Carcinoma of the Pancreas: Case Report with Review of Literature

MASAYOSHI HIOKI1, TOSHIO NAKAGOHRI2, TARO IKUMOTO3, NAOTO GOTOHDA1, SHINICHIRO TAKAHASHI1, MASARU KONISHI1, MOTOHIRO KOJIMA4 and TAIRA KINOSHITA1

1Division of Digestive Surgery, and 4Division of Clinical Pathology, National Cancer Center Hospital East, Chiba, Japan; 2Division of Surgery, Tokai University School of Medicine, Kanagawa, Japan; 3Division of Surgery, Sano Hospital, Kobe, Japan

Abstract. A 67-year-old man presented with leg edema. Laboratory data showed elevated blood glucose and carbohydrate antigen (CA) 19-9 levels, and anemia. Further imaging studies revealed a relatively clear-margined tumor totally occupying the main pancreatic duct (MPD) from the head to the tail of the pancreas (maximum diameter 10 cm) without mucin hypersecretion. Total pancreatectomy with splenectomy and regional lymphadenectomy were performed. Intraductal tubular carcinoma (ITC) was diagnosed by immunohistochemical staining and electron microscopic examination. Previous reports showed that this tumor is characterized by slow growth, with a favorable prognosis and intraductal nodular growth occupying the MPD and no macroscopic mucus. Whether ITC should be distinguished from other types of pancreatic neoplasm is controversial, and the accumulation of more ITC cases and multi-institutional analysis are necessary to establish the diagnostic criteria and characteristics of this histological entity.

Intraductal tubular neoplasm (ITN), with tubular architecture or scant mucus production, has recently been described as a variant of intraductal neoplasm of the pancreas. This type of tumor is described in a recent Armed Forces Institute of Pathology series (1) and in the General Rules for the Study of Pancreatic Cancer published by the Japan Pancreas Society (2), ITN is classified as a subtype of intraductal papillary-mucinous neoplasm (IPMN) (4). ITN is further classified into intraductal tubular adenoma and intraductal tubular carcinoma (ITC). To date, only fifteen cases of ITC have been reported in the clinical literature (5-14).

The Authors recently encountered a case of ITC in which it was difficult to make a decisive pathological diagnosis.

Case Report

A 67-year-old man attended a local hospital with chief complaint of leg edema. Peripheral blood examination revealed severe anemia (Hb: 6.4 g/dl). Gastrointestinal endoscopy showed a duodenal tumor, and adenocarcinoma was confirmed histologically. He was referred to our hospital for further examinations. Physical examination revealed no findings except for leg edema. The results of hematological, general biochemical, and urinalysis tests were all within the normal ranges, except for elevated blood glucose (155 mg/dl), CA19-9 (58.3 U/ml), and anemia (Hb: 9.9 g/dl).

Gastrointestinal endoscopy showed an ulcerated tumor with sharply demarcated margins on the wall of the duodenum. The papilla of Vater was swollen (Figure 1). Enhanced computed tomography (CT) detected a low density, relatively clear-margined tumor, with maximum diameter of 10 cm in the pancreatic head. The tumor totally occupied the main pancreatic duct (MPD) from the head to the tail of the pancreas. The duodenum was definitely invaded by the tumor. The tumor was close to the portal vein (Figure 2). Even with the use of magnetic resonance (MR) imaging with MR cholangiopancreatography (MRCP) it was not possible to identify the MPD. Diffusion-weighted image showed a high intensity mass in the head of the pancreas. A high intensity tumor was also observed in the distal pancreas (Figure 3).

Based on the findings of these examinations, we made a tentative preoperative diagnosis of acinar cell carcinoma (ACC).
with intraductal spread of the pancreas. Total pancreatectomy with splenectomy and regional lymphadenectomy were performed. The patient's postoperative course was uneventful, and he remains alive 3 years after the operation without any symptoms or signs of tumor recurrence.

Macroscopically, the tumor was 6.5 cm in maximum diameter. The lumen of the MPD was totally filled with solid and hemorrhagic tumor. There was no mucus hypersecretion (Figure 4). The tumor was exposed to the duodenal bulb. Microscopically, the main pancreatic duct was filled with

Figure 1. Gastrointestinal endoscopy showed an ulcerated tumor with sharply demarcated, raised margins in the wall of the duodenal bulb (A). The papilla of Vater was swollen (B).

Figure 2. Enhanced computed tomography detected a low density, relatively clear-margined tumor with maximum diameter of 10 cm in the pancreatic head. The tumor totally occupied the main pancreatic duct from the head to the tail of the pancreas. The duodenum was clearly invaded by tumor (A). The tumor was close to the portal vein (B).
tumor cells, and the epithelium of most of the pancreatic duct contained atypical cells. The tumor showed small tubular structures, and tumor cells had granular and eosinophilic cytoplasm. Partially eosinophilic cells showed a sheet-like distribution. Most of the tumor was confined to the intraductal but with focal invasion to the duodenum. Periodic acid-Schiff (PAS) and diastase digestive PAS staining showed intracytoplasmic mucin secretion (Figure 5). Immunohistochemical investigation showed the tumor cells to strongly express alpha-1-antitrypsin, cytokeratin (CK) 7, CK19, cancer antigen (CA) 19-9, and MUC1, and to weakly express amylase focally, whereas trypsin, chromogranin A, synaptophysin, cluster of differentiation (CD) 56, CK20 were not expressed (Figure 6). Electron microscopic examination did not reveal zymogen granules in the tumor cells (Figure 7). The final diagnosis was T3N1M0 stage ITC.

Figure 3. Even with the use of Magnetic resonance (MR) imaging with MR cholangiopancreatography, it was not possible to identify the MPD (A). Diffusion-weighted image showed a high intensity mass in the head of the pancreas. High intensity was also observed the distal pancreas (B).

Figure 4. Macroscopically, the tumor was 6.5 cm in maximum diameter. The lumen of the MPD was totally filled with solid and hemorrhagic tumor. There was no mucus hypersecretion.
Discussion

Intraductal neoplasms of the pancreas include IPMN (4), pancreatic intraepithelial neoplasia (PanIN) (15), ITN and an intraductal variant of ACC (16-18). In this case, it was difficult to make a decisive pathological diagnosis. This case was different from ordinary IPMN or PanIN because there was a predominantly tubular neoplasm and an absence of mucus hypersecretion. Macroscopic intraductal tumors without mucus hypersecretion such as in this case, which include ACC (16-18), endocrine tumor (19, 20), and ITN, have been recently reported. This case resembled ACC in macroscopic and microscopic

Figure 5. Microscopically, tumor cells filled the entire pancreatic duct (A), and the epithelium of most of the pancreatic duct contained atypical cells (B). The tumor exhibited small tubular structures, and tumor cells had granular and eosinophilic cytoplasm (C, D). PAS and diastase digestive PAS staining showed intracytoplasmic mucin secretion (E).
appearance, and thus it was very difficult to differentiate it from ACC. In view of the ductal structure with intracytoplasmic mucin histologically, the expression of ductal markers CK7, CK19, and CA19-9 immunohistochemically, and the predominant intraductal spread of MUC1-positive cells, this case was diagnosed as ITC. Weak, focal expression of amylase was seen immunohistochemically. However, electron microscopic examination did not reveal zymogen granules in the tumor cells. So this case was ultimately diagnosed as ITC.

ITC is an extremely rare pancreatic tumor that exhibits a nodular or polypoid gross appearance with a monotonous tubular growth pattern and no papillary projections or mucin

Figure 6. Immunohistochemical investigation showed the tumor cells strongly expressed alpha-1-antitrypsin (A), CK7 (B), CA19-9 (C), and MUC1 (D), and had weak focal expression of amylase (E), whereas trypsin (F) was not expressed.
hypersecretion in the pancreatic ducts. Based on a MEDLINE search from 1980 through 2009, fifteen cases of ITC have been reported (5-14) (Table I). All fifteen ITC cases showed characteristics of intraductal nodular growth, occupying the MPD without macroscopic mucus hypersecretion. Suda et al. reported four cases of ITC with relatively longer survival despite invasion and metastasis to lymph nodes (5). Despite tumor invasion to the duodenum and metastasis to lymph nodes, our patient has survived for more than 28 months without any sign of recurrence. These results suggest that ITC is a slow-growing tumor with a favorable prognosis.

In summary, we had difficulty diagnosing this case precisely from morphologic findings alone. The results of immunohistochemical staining in reported cases were also not consistent (Table II). We diagnosed this case as ITC ultimately because of the findings of immunohistochemical staining and electron microscopic examination. Previous reports have suggested that this tumor is characterized by slow growth with intraductal nodular growth occupying the MPD and no macroscopic mucus, with a favorable outcome in the majority of cases. Whether ITN should be distinguished from other types of pancreatic neoplasm is controversial, and the accumulation of more ITN cases and multi-institutional analysis are necessary to establish the diagnostic criteria and characteristics of this histological entity.

References


Table II. Immunohistochemical data of ITC.

<table>
<thead>
<tr>
<th>Authors</th>
<th>PAS-AB</th>
<th>MUC-1</th>
<th>MUC-2</th>
<th>MUC-5</th>
<th>MUC-6</th>
<th>CA19-9</th>
<th>CEA</th>
<th>Dupan-2</th>
<th>P53</th>
<th>Chromogranin</th>
<th>Synaptophysin</th>
<th>Trypsin</th>
<th>Chymotrypsin</th>
<th>Amylase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ito et al. (7)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tajiri et al. (8)</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>++</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Tajiri et al. (8)</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Tajiri et al. (8)</td>
<td>–</td>
<td>++</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Tajiri et al. (8)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Iatsu et al. (9)</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Thirot-Bidault et al.</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td></td>
<td></td>
<td></td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Hisa et al. (11)</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
<td>–</td>
<td></td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Oh et al. (12)</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td></td>
<td></td>
<td></td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Furukawa et al. (13)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Terada et al. (14)</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td></td>
<td>+++</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Present case</td>
<td>+</td>
<td>++</td>
<td></td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
</tr>
</tbody>
</table>

ITC, Intraductal tubular carcinoma; PAS, periodic acid-Schiff staining; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; –, negative; +, <30% or partially positive; ++, >30%.


Received June 30, 2010
Revised July 29, 2010
Accepted August 13, 2010